Literature DB >> 8629722

Clinical and prophylactic trials with assured new treatment for those at greater risk: II. Examples.

M O Finkelstein1, B Levin, H Robbins.   

Abstract

OBJECTIVES: The preceding article proposed an assured treatment design that would address certain difficulties in recruiting persons who are at greater risk into randomized clinical trials. The purpose of this article is to illustrate the statistical validity of the design in a practical setting.
METHODS: Three actual randomized clinical trials were considered as case studies; in each, the data that would have been obtained under assured allocation were identified. Then, with only these data, together with a reasonable choice of model describing the response of subjects under standard treatment as a function of initial severity, the treatment effect was estimated for the subjects at greater risk. The estimates were compared with conventional estimates for the sicker patients randomized in the original trials.
RESULTS: In each case, the estimates produced in the assured treatment trial were close to those observed in the randomized trial.
CONCLUSIONS: Risk-based allocation trials deserve serious consideration when randomized clinical trials are difficult or impossible to execute. The proposed designs and analyses would allow physicians to offer persons at greater risk assurance that they would receive the new treatment, while researchers would retain the ability to draw valid statistical conclusions about treatment efficacy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8629722      PMCID: PMC1380479          DOI: 10.2105/ajph.86.5.696

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  4 in total

1.  A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.

Authors:  M A Fischl; C B Parker; C Pettinelli; M Wulfsohn; M S Hirsch; A C Collier; D Antoniskis; M Ho; D D Richman; E Fuchs
Journal:  N Engl J Med       Date:  1990-10-11       Impact factor: 91.245

2.  Estimating the superiority of a drug to a placebo when all and only those patients at risk are treated with the drug.

Authors:  H Robbins; C H Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

3.  A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.

Authors:  J O Kahn; S W Lagakos; D D Richman; A Cross; C Pettinelli; S H Liou; M Brown; P A Volberding; C S Crumpacker; G Beall
Journal:  N Engl J Med       Date:  1992-08-27       Impact factor: 91.245

4.  Clinical and prophylactic trials with assured new treatment for those at greater risk: I. A design proposal.

Authors:  M O Finkelstein; B Levin; H Robbins
Journal:  Am J Public Health       Date:  1996-05       Impact factor: 9.308

  4 in total
  9 in total

1.  Application of regression-discontinuity analysis in pharmaceutical health services research.

Authors:  Ilene H Zuckerman; Euni Lee; Anthony K Wutoh; Zhenyi Xue; Bruce Stuart
Journal:  Health Serv Res       Date:  2006-04       Impact factor: 3.402

2.  Alternatives to the randomized controlled trial.

Authors:  Stephen G West; Naihua Duan; Willo Pequegnat; Paul Gaist; Don C Des Jarlais; David Holtgrave; José Szapocznik; Martin Fishbein; Bruce Rapkin; Michael Clatts; Patricia Dolan Mullen
Journal:  Am J Public Health       Date:  2008-06-12       Impact factor: 9.308

Review 3.  [Clinical studies in oncology. Relevance, design, ethical considerations].

Authors:  B Wörmann; G Wulf; W Hiddemann
Journal:  Med Klin (Munich)       Date:  1998-03-15

4.  Continuous evaluation of evolving behavioral intervention technologies.

Authors:  David C Mohr; Ken Cheung; Stephen M Schueller; C Hendricks Brown; Naihua Duan
Journal:  Am J Prev Med       Date:  2013-10       Impact factor: 5.043

5.  The promise of risk-based allocation trials in assessing new treatments.

Authors:  F Mosteller
Journal:  Am J Public Health       Date:  1996-05       Impact factor: 9.308

6.  Treatment research for children and youth exposed to traumatic events: moving beyond efficacy to amp up public health impact.

Authors:  David J Kolko; Kimberly Eaton Hoagwood; Benjamin Springgate
Journal:  Gen Hosp Psychiatry       Date:  2010-08-11       Impact factor: 3.238

7.  Clinical and prophylactic trials with assured new treatment for those at greater risk: I. A design proposal.

Authors:  M O Finkelstein; B Levin; H Robbins
Journal:  Am J Public Health       Date:  1996-05       Impact factor: 9.308

Review 8.  Approaches to Mixed Methods Dissemination and Implementation Research: Methods, Strengths, Caveats, and Opportunities.

Authors:  Carla A Green; Naihua Duan; Robert D Gibbons; Kimberly E Hoagwood; Lawrence A Palinkas; Jennifer P Wisdom
Journal:  Adm Policy Ment Health       Date:  2015-09

9.  Regression discontinuity designs in epidemiology: causal inference without randomized trials.

Authors:  Jacob Bor; Ellen Moscoe; Portia Mutevedzi; Marie-Louise Newell; Till Bärnighausen
Journal:  Epidemiology       Date:  2014-09       Impact factor: 4.822

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.